Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines

Hepatology

Volumn 33, Issue 5, 2001, Pages 1087-1097

  Koga, Hironori ^a   Sakisaka, Shotaro ^b   Harada, Masaru ^a   Takagi, Toshiyuki ^c   Hanada, Shinichiro ^a   Taniguchi, Eitaro ^a   Kawaguchi, Takumi ^a   Sasatomi, Kurumi ^a   Kimura, Rina ^a   Hashimoto, Osamu ^a   Ueno, Takato ^a   Yano, Hirohisa ^a   Kojiro, Masamichi ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CELL CYCLE PROTEIN; CIGLITAZONE; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DELTA12 PROSTAGLANDIN J2; DNA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PROTEIN P18; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; CYTOSTASIS; FLOW CYTOMETRY; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 0035035402     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.24024     Document Type: Article

References (41)

1. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
2. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
3. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor
4. Differentiation and reversal of malignant changes in colon cancer through PPARγ
5. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
6. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
7. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
8. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis
9. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
10. Cyclin dependent kinase regulation
11. Inhibitors of mammalian G1 cyclin-dependent kinases
12. The retinoblastoma protein and cell cycle control
13. Role of PPARg in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18 (INK4c) and p21 (Waf1/Cip1), during adipogenesis
14. Establishment of two distinct human hepatoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells
15. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines
16. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment
17. A novel method for real time quantitative RT-PCR
18. Real-time quantitative RT-PCR after laser-assisted cell picking
19. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ
20. Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
21. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor d in colorectal cancer
22. Involvement of p21 (WAF1/Cip1) and p27 (Kip1) in intestinal epithelial cell differentiation
23. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor
24. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
25. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA
26. Functional analysis of a p21WAF1, CIP1, SDI1 mutant (Arg94 → Trp) identified in a human breast carcinoma: Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases
27. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway
28. Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas
29. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers
30. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
31. p27 expression and gastric carcinoma
32. Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells
33. Kip1, polyploidy and centrosome over-duplication
34. Control of E2F activity by p21Waf1/Cip1
35. Terminal differentiation of human breast cancer through PPARγ
36. Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma
37. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice
38. Pharmacodynamics of immediate and delayed effects of paclitaxel: Role ofslow apoptosis and intracellular drug retention
39. Expression of transforming growth factor alpha in the liver before and after interferon alpha therapy for chronic hepatitis B
40. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
41. Peroxisome proliferator-activated receptor γ transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells